Today's news includes a report on Pfizer's strong financial results for 2024 and their expectations for 2025. Pfizer had revenues of $63.6 billion in 2024, and their net income was $8.031 billion. They also reported earnings per share of $1.41 for the full year and $0.07 for the fourth quarter. In 2025, Pfizer expects revenues between $61.0 to $64.0 billion and adjusted earnings per share between $2.80 to $3.00. Pfizer also discussed their operational progress, successful product launches, and cost-saving strategies to improve shareholder value. They mentioned developments in cancer treatments and other pharmaceutical projects. Pfizer also noted strategic organizational changes and environmental sustainability goals. The report also highlighted risks and uncertainties Pfizer faces, such as regulatory challenges, market competition, cyber threats, government regulations, legal actions, intellectual property risks, and economic factors. Overall, Pfizer is focused on innovation, growth, and delivering value to their stakeholders while addressing potential challenges in the pharmaceutical industry.